Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

View All Documentation

L3791

Sigma-Aldrich

Lamotrigine

≥98% (TLC), powder, glutamate release inhibitor

Synonym(s):

6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, GI 267119X

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
$153.90
50 MG
$633.60

$153.90

List Price$171.00Save 10%
Web-Only Promotion

Available to ship onMay 13, 2025Details

Request a Bulk Order
All Photos(2)

Select a Size

Change View
10 MG
$153.90
50 MG
$633.60

About This Item

Empirical Formula (Hill Notation):
C9H7Cl2N5
CAS Number:
84057-84-1
Molecular Weight:
256.09
EC Number:
281-901-8
MDL number:
MFCD00865333
UNSPSC Code:
12352200
PubChem Substance ID:
24278792
NACRES:
NA.77

$153.90

List Price$171.00Save 10%
Web-Only Promotion

Available to ship onMay 13, 2025Details

Request a Bulk Order

Product Name

Lamotrigine, ≥98%, powder

Quality Level

200

assay

≥98%

form

powder

color

white

solubility

DMSO: soluble 20 mg/mL at 60 °C
H2O: insoluble

originator

GlaxoSmithKline

storage temp.

2-8°C

SMILES string

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

InChI key

PYZRQGJRPPTADH-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
rat ... Scn2a1(24766) , Scnn1a(25122)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Anticonvulsant.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCW2040
MKCH9792
MKCF2209
MKCB1463V
MKBV1400V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stacey Shim et al.
The Journal of pharmacology and experimental therapeutics, 347(2), 487-496 (2013-08-30)
Carisbamate and lamotrigine are anticonvulsants that act on neuronal voltage-gated sodium channels. Carisbamate has shown antidepressant-like effects in animal models of depression, and lamotrigine is a mood stabilizer with a therapeutic effect in depressive episodes of patients with bipolar disorder.
Kerstin Römermann et al.
Neuropharmacology, 93, 7-14 (2015-02-04)
Resistance to antiepileptic drugs (AEDs) is the major problem in the treatment of epilepsy. One hypothesis to explain AED resistance suggests that seizure-induced overexpression of efflux transporters at the blood-brain barrier (BBB) restricts AEDs to reach their brain targets. Various
Allyson K Friedman et al.
Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)
Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA
Philip J Wiffen et al.
The Cochrane database of systematic reviews, (2)(2), CD006044-CD006044 (2011-02-18)
This is an update of the original Cochrane review published in Issue 2, 2007. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This updated review adds five new additional studies looking
Jacqueline A French et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 9(1), 176-184 (2011-12-06)
The efficacy and safety of lamotrigine extended-release tablets (LTG XR) as monotherapy for partial seizures were evaluated using the conversion-to-monotherapy design, and historical data as the control. This methodology was recently approved by the United States Food and Drug Administration
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service